The Bio Report

In cancer, synthetic lethality refers to a state in which two genetic mutations that alone may allow a cancer cell to survive will kill it when they exist simultaneously. Cyteir Therapeutics is seeking to exploit that strategy with what it calls next-generation synthetically lethal therapies to treat a wide range of cancers. We spoke to Markus Renschler, president and CEO of Cyteir therapeutics, about synthetic lethality, Cyteir’s pipeline, and life as a small public biotech in 2022.